1 completed, 1 recruiting, 1 withdrawn. 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Metastatic Bone Sarcoma: new trials by email Literature Review of Metastatic Bone Sarcoma trials Research Report on Metastatic Bone Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine With Ascorbate Including Adolescents Ascorbate, Gemcitabine - Soft Tissue Sarcoma, Bone Sarcoma | Early Phase 1 | Withdrawn | David Dickens | 2023-01-01 | 2023-02-22 | |
| Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy - Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 99 | 2020-07-16 | 2026-08-21 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 164 | 2015-08-13 | 2023-10-17 |
Bone Neoplasms (3) · Sarcoma (3) · Colorectal Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma (1)
Bone Diseases (3) · Musculoskeletal Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Connective and Soft Tissue (3) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Histiocytoma (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms, Adipose Tissue (1)
1,2-diaminocyclohexaneplatinum II citrate (1) · Ascorbic Acid (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Gemcitabine (1) · Ipilimumab (1) · Metastasectomy (1) · Nivolumab (1) · Platinum (1)
David Dickens (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1)
United States (3)
David Dickens, MD, FAAP (1) · Kenneth Seastedt (1) · Sandra P D'Angelo (1)
U10CA180821 (1)